Immutep Limited Stock Australian S.E.
Stocks
IMMAQ
AU0000281537
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 81.05M 56.25M 49.26M 45.37M 42.11M 79.97M 5.37B 543M 211M 2.63B 211M 207M 9.13B | P/E 2026 * |
-1.4x | P/E 2027 * | -1.99x |
|---|---|---|---|---|---|
| Enterprise Value | 15.96M 11.08M 9.7M 8.94M 8.29M 15.75M 1.06B 107M 41.63M 519M 41.6M 40.69M 1.8B | EV / Sales 2026 * |
0.93x | EV / Sales 2027 * | 1.2x |
| Free-Float |
96.98% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Voigt
CEO | Chief Executive Officer | 53 | 09/07/2014 |
David Fang
DFI | Director of Finance/CFO | - | 01/03/2018 |
Stephan Winckels
CTO | Chief Tech/Sci/R&D Officer | - | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Voigt
BRD | Director/Board Member | 53 | 09/07/2014 |
Russell Howard
CHM | Chairman | 76 | 17/11/2017 |
Pete Meyers
BRD | Director/Board Member | 57 | 12/02/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 56.25M | |
| -1.03% | +5.24% | +2.94% | +9.41% | 50.25B | |
| -0.06% | +1.11% | +416.38% | +617.53% | 40.39B | |
| +1.15% | +7.94% | +28.39% | -3.80% | 34.38B | |
| -1.25% | +7.18% | +26.74% | +61.14% | 34.4B | |
| +1.31% | -0.56% | +5.12% | +33.90% | 26.32B | |
| +2.02% | +2.55% | - | - | 16.64B | |
| -2.64% | +3.58% | +72.01% | +132.90% | 16.14B | |
| +0.32% | +0.53% | +14.33% | +21.47% | 13.71B | |
| +3.07% | +7.61% | +104.22% | +104.22% | 13.75B | |
| Average | +0.33% | +3.64% | +83.77% | +122.09% | 27.33B | |
| Weighted average by Cap. | +0.14% | +4.10% | +95.00% | +140.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 17.23M 11.96M 10.47M 9.65M 8.95M 17M 1.14B 115M 44.94M 560M 44.91M 43.92M 1.94B | 3.15M 2.19M 1.92M 1.76M 1.64M 3.11M 209M 21.12M 8.22M 102M 8.21M 8.03M 355M |
| Net income | -58.54M -40.62M -35.58M -32.77M -30.42M -57.76M -3.87B -392M -153M -1.9B -153M -149M -6.59B | -47.05M -32.65M -28.6M -26.34M -24.45M -46.42M -3.11B -315M -123M -1.53B -123M -120M -5.3B |
| Net Debt | -65.09M -45.17M -39.56M -36.43M -33.82M -64.22M -4.31B -436M -170M -2.11B -170M -166M -7.33B | -77.26M -53.61M -46.95M -43.25M -40.14M -76.23M -5.11B -518M -201M -2.51B -201M -197M -8.7B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
